Ladostigil: Phase IIb ongoing

Avraham said an independent expert committee concluded there were no serious or unexpected adverse events preventing continuation of a double-blind, placebo-controlled, international Phase IIb trial of ladostigil based on safety data from patients who have completed >=1 year of treatment. The trial is evaluating 10 mg oral ladostigil once daily for 3 years in about 200 patients. Avraham also said there were positive efficacy trends, including reduced loss of brain volume as determined by MRI, improved immune system parameters and trends of improvement in cognitive parameters. The company expects interim data in 3Q15 and final data in 3Q16. ...